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Pain is the main symptom in most rheumatic and musculoskeletal diseases (RMDs). It has 
debilitating effects in terms of mobility, physical function, sleep, mood, fatigue and overall 
quality of life. This is why pain and its associates are some of the predominant outcomes 
evaluated regularly in response to pharmaceutical or any other interventions involved in the 
management of RMDs.  
 
The source of pain in RMDs seems to be mainly inflammation and/or damage of affected joints, 
while changes in central nervous system processing contribute significantly to it’s chronicity  
[reviewed comprehensively by Salaffi and colleagues (1)]. In line with this, the implementation 
of treat-to target approaches seem to effectively reduce pain scores (2), most likely by 
suppressing inflammation in the short term and inhibiting joint damage in the longer term. In 
general, patients treated with disease modifying anti-rheumatic drugs (DMARDs) experience 
alleviation in pain in the short term, with follow-up long-term studies suggesting that their 
effects on pain are much less clear (3). Joint replacement, on the other hand, can also reduce 
pain, supporting the notion that treating structural and functional joint disease-induced 
alterations can also significantly reduce pain in RMDs (4).  
 
It is alarming that 75% of European and 82% of US patients with rheumatoid arthritis report 
moderate-to-severe pain in the last two months (5), irrespective of treatment or disease 
duration. Despite a significant amount of research in this area, pain still remains a challenging 
area of investigation, without a clear understanding of how it can be drastically and effectively 
managed. The lack of significant progress on how best to treat this important outcome is 
denoted in recent efforts, such as the 2018 European League Against Rheumatism (EULAR) 
recommendations on pain management in RMDs (6).  
 
Exercise, a part of the general spectrum of physical activity, is planned and structured physical 
activity done with the intention to improve health outcomes. Exercise improves health 
outcomes in a dose-dependent manner; thus, higher exercise intensities will have better health 
effects compared to lower exercise intensities. However, the concept of “high-intensity 
exercise” is perceived by many patients with RMDs as something they should avoid, as they 
fear that it may exacerbate disease symptoms and join damage (7), a view that RMD 
professionals lack the confidence to appropriately address in their consultations with RMD 
patients (8). This is despite a great number of research studies demonstrating that exercise 
(even high-intensity), not only is safe, but can also ameliorate disease-related symptoms [such 
as pain and fatigue (9, 10)] and systemic aspects of RMDs [such as cardiovascular risk and 
rheumatoid cachexia (9, 11, 12)]. However, it is important to note that patients with RMDs 
report pain as one of the main barriers that stops them from engaging in exercise (7). This may 
be because patients fear that exercise may induce further joint damage, particularly when the 
exercises are painful; however, painful exercises may have the potential to reconceptualize 
pain related fear and as a result, help these patients to engage in such activities (13).  
 
Blocking tumor necrosis factor alpha (TNFa) via anti-TNFa medication seems to result in an 
increased engagement in physical activity in rheumatic diseases (14); if this is because of 
reductions in pain and/or symptom alleviation, still remains to be investigated. Given the 
multiple benefits of physical activity and exercise in RMDs with pain being an important 
barrier for lack of engagement, the question arises as to whether patients should increase their 
intake of pain relief medication in order to engage in exercise. In the absence of any robust 
studies in this field of investigation, the short answer is no, and this is for the following reasons:  
 
Exercise may potentially reduce pain as an intervention in itself: Exercise per se is an 
intervention that seems to have beneficial effects in alleviating pain in people with rheumatic 
disease. A 2009 meta-analysis in the Cochrane Library has evaluated the effects or aerobic and 
strength training on pain outcomes in rheumatoid arthritis patients (9) and revealed that pain 
can be reduced by an absolute 6% after 12 weeks of exercising; whether this represents a 
clinically significant reduction is uncertain. In general, exercise can induce analgesia via 
activating central inhibitory pathways.  Serotonin, opioids and N-methyl-D-aspartase (NMDA) 
related mechanisms that act on the rostral ventromedial medulla [a group of neurons located in 
the middle line of the medulla oblogata (in the brainstem)] can be induced by exercising (15) 
with pain-reducing effects in exercising adults. Although this establishes biological 
plausibility, a recent 2017 umbrella Cochrane review (including 21 reviews with 381 included 
studies and 37,143 patients with chronic pain) suggested an overall favourable effect of 
exercise in reducing pain severity, but this is small to moderate and not consistently observed 
in all studies (16). In contrast, a 2017 meta-analysis from a EULAR Taskforce conducted 
specifically in people with RMDs suggested that exercise associated with more uniformly 
positive effects on pain management (6), which is a positive finding and specific to RMDs. As 
such,  because pain has great within-person variability, not only within a day but also between 
days (17), perhaps engaging people with RMDs in exercise at times when pain is experienced 
less, should be considered as an option prior to giving pain-relief medication in order to engage 
in exercise.  
 
Increasing pain relief medication may have adverse effects: Non-steroidal anti-inflammatory 
drugs (NSAIDs) are amongst the most commonly prescribed drugs for managing pain in RMDs 
but their use can be unfortunately associated with gastrointestinal side-effects (18), increased 
cardiovascular risk and premature mortality (19). Even in healthy athletes, who tend to use 
NSAIDs to alleviate exercise-induced pain, a small relevant study demonstrated that 
administration of ibuprofen aggravates the exercise-induced small intestinal injury (20) while 
NSAIDs seem ineffective in alleviating pain from muscle damage (21). The latter, is a very 
frequent phenomenon caused by high-intensity exercise but is actually necessary for beneficial 
physiological adaptations (e.g. muscle mass increase) that can improve balance, cachexia (loss 
of muscle mass), functional disability and other outcomes in people with RMDs. Significantly 
fewer side-effects are seen with the use of acetaminophen (paracetamol) vs. NSAIDs in athletes 
(22). However, in patients with RMDs that are already subjected to polypharmacy (23), this 
may not be an absolutely safe approach, as increases in acetaminophen use could potentially 
result in further side effects. Even in healthy adults, the usual recommended dose of 4 g/d of 
acetaminophen may associate with elevated aminotransferases (24). The most recent EULAR 
recommendations for managing pain in rheumatic conditions suggest usage of paracetamol, 
topical NSAIDs and capsaicin as first-line treatments, with the potential side-effects of 
NSAIDs to be taken into account when prescribing such agents (6).  
 
Drug treatment alone does not seem to be an ideal solution for pain care: Compared to 
treatment advances in other areas of rheumatic diseases (e.g. inflammation control), pain 
management in RMDs is still in its infancy. Any enthusiasm around the usage of pain relief 
medications to facilitate and enable engagement in exercise should be tempered by the absence 
of relevant studies establishing either efficacy or safety in this particular context. Given that 
factors other than inflammation and joint damage, such as depression, obesity, demographic 
and social factors (1, 5) associate with pain in RMDs, it is likely that (any) medication on its 
own is insufficient for pain management in people with RMDs. Educational interventions, 
exercise, orthotics, weight management, psychological interventions and other 
multidisciplinary approaches have been successfully used for the management of pain in RMDs 
(6), however, their utility in the context of exercise has not been assessed.  
 
Pain is the cardinal symptom in most RMDs, has many dimensions and is one of the main 
barriers to exercise. Exercise, in turn, has multiple indisputable health benefits in this 
population, including reduced pain in RMDs. The use of pain medication alone as a means to 
enable people with RMDs to exercise cannot be supported at this stage, due to lack of evidence 
for efficacy and safety in this particular context. It is likely that a more comprehensive lifestyle 
approach alongside a reconceptualization of pain acting as a barrier to engage in such lifestyles 
are both necessary. Both the individual components (including pain medication) and the overall 
lifestyle approach need to be prospectively evaluated in studies designed specifically for the 
purpose.    
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